IP Library › Granted Patent US 12,186,294
Granted Patent B2
US 12,186,294 · App. 16/780,604 · Granted Jan 7, 2025

Modulators of prostate-specific g-protein receptor (PSGR/OR51E2) and methods of using same

Inventors: Tatjana Abaffy (Durham, NC); Hiro Matsunami (Durham, NC)
Assignee: Duke University
A61K31/203A61K31/19A61K31/352A61K31/565A61K31/568A61K31/7016A61K47/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,186,294
App. No.
16/780,604
Granted
Jan 7, 2025
Kind
B2
Abstract

The present disclosure provides, in part, modulators of prostate-specific G-protein receptor (OR51E2/PSGR) and methods of treating, preventing, and diagnosing prostate cancer using the same.

Claims (11)

1. A method of diagnosing neuroendocrine trans-differentiation of prostate cancer in a subject, the method comprising:

i) obtaining a biological sample from the subject, wherein the biological sample comprises prostate cancer cells, wherein the prostate cancer cells express OR51E2;

ii) contacting the sample with one or more OR51E2 ligands, wherein the one or more OR51E2 ligands are 19-hydroxyandrost-4-ene-3,17-dione (19-OH AD), N-acetyl-N-formyl-5-metoxykynurenamine (AFMK), propionic acid (PA), or any combination thereof;

iii) detecting decreases in the levels of metabolites in the sample from step ii) after contacting the sample with one or more OR51E2 ligands as compared to a control sample, wherein the more metabolites comprise lactic acid, serine, threonine, glucose-6 phosphate, fructose-6 phosphate, fumaric acid, glutamic acid, beta-alanine, ornithine, and inosine;

iv) detecting increases in the levels of compounds in the sample from step ii) after contacting the sample with one or more OR51E2 ligands as compared to a control sample, wherein the compounds comprise phosphoenolpyruvate, cysteine, asparagine, glutaric acid, guanine, and glutamine; and

v) identifying the presence of neuroendocrine trans-differentiation of prostate cancer in a subject based on the decreases in the levels of the metabolites and the increases in the levels of the compounds.

2. The method of claim 1 , wherein the presence of castrate-resistant prostate cancer is identified.

3. The method of claim 1 , wherein the presence of neuroendocrine trans-differentiation of prostate cancer cells is identified.

4. The method of claim 1 , wherein the one or more OR51E2 ligand of step ii) comprises 19-OH.

5. The method of claim 1 , wherein the one or more OR51E2 ligand of step ii) comprises AFMK.

6. The method of claim 1 , wherein the one or more OR51E2 ligand of step ii) comprises PA.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2022
From: ABAFFY, TATJANA; MATSUNAMI, HIRO
To: DUKE UNIVERSITY
Reel/Frame 060736/0878 →
Continuity (3)
Division 15801258 · Nov 1, 2017
Provisional Application 62415591 · Nov 1, 2016
Related Publication 20200253912A1 · Aug 13, 2020
References Cited (18)
US 20090075284A1 · Chinnaiyan · 2009 [cited by examiner]
US 20100292331A1 · Mitchell · 2010 [cited by examiner]
US 20100298270A1 · Keana et al. · 2010 [cited by applicant]
Cao et al. BMC Cancer, 2015, 15:915, 9 pages (Year: 2015). [cited by examiner]
Maßberg et al. Oncotarget, 2016, vol. 7, No. 30, pp. 48231-48249 (Year: 2016). [cited by examiner]
Marberger et al. British Medical Journal, Mar. 24, 1962, pp. 835-836 (Year: 1962). [cited by examiner]
Song et al. Amino Acids, 2012, vol. 42, pp. 1897-1902 (Year: 2012). [cited by examiner]
Struck-Lewicka et al. Journal of Pharmaceutical and Biomedical Analysis, 2015, vol. 111, pp. 351-361 (Year: 2015). [cited by examiner]
Neuhaus et al., “Activation of an olfactory receptor inhibits proliferation of prostate cancer cells”, Journal of Biological Chemistry, 284(24):16218-25 (Jun. 2009). Epub Apr. 2009. [cited by applicant]
Zhuang et al., “Evaluating cell-surface expression and measuring activation of mammalian odorant receptors in heterologous cells”, Nature Protocols, 3(9):1402-13 (2008). [cited by applicant]
Xu et al., “PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer”, Cancer Research, 60(23):6568-72 (Dec. 2000). [cited by applicant]
Luciferase Reporters, ThermoFisher Scientific, [retrieved on Apr. 2, 2018] [retrieved from the internet http://www.thermofisher.com/us/en/home/life-science/protein-biology/protein-biology-learning-center/protein-biology… [cited by applicant]
Dipaola et al., “A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate… [cited by applicant]
Abaffy et al., “A Testosterone Metabolite 19-Hydroxyandrostenedione Induces Neuroendocrine Trans-Differentiation of Prostate Cancer Cells via an Ectopic Olfactory Receptor,” Front. Oncol., 8:162 (May 2018) [15 pages]. [cited by applicant]
Dahiya et al., “Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid,” Int J. Cancer, 59(1):126-32 (Oct. 1994). [cited by applicant]
Schäfer et al., “Failure is an option: learning from unsuccessful proof-of-concept trial,” Drug Discov Today, 13 (21-22):913-6 (Nov. 2008) Epub Jun. 2008. [cited by applicant]
Horig et al., “From bench to clinic and back: Perspective on the 1st IQPC Translational Research conference,” J. Transl Med., 2(1):44 (Dec. 2004). [cited by applicant]
Johnson et al., “Metabolomics: beyond biomarkers and towards mechanisms,” Nat Rev Mol Cell Biol. (Jul. 2016); 17(7):451-459. [cited by applicant]